Home · For Physicians · Pain Management

Pain management

ENFD testing for pain management practices

When nerve conduction studies and EMG, which only assess large fibers, come back normal in a patient with burning, tingling, or numbness, ENFD is often the test that finally confirms small fiber neuropathy (SFN) and gives you an objective, reportable diagnosis to act on.

A physician at a desk reviewing an imaging scan on a tablet next to a laptop

Small fiber neuropathy

A cause of burning pain that large-fiber studies can miss.

Small fiber neuropathy is a disorder of the peripheral nerves that affect small somatic fibers, autonomic fibers, or both, resulting in sensory changes and/or autonomic dysfunction when both types of fibers are involved.

Symptoms of SFN include pain, burning, tingling and numbness. These symptoms often start in the feet and progress up the rest of the body. Symptoms are often worse at night and affect sleep.

EMG/NCS only evaluate large myelinated fibers, so patients with painful small fiber neuropathy routinely test “normal” on those studies alone.

A working laboratory bench with pipettes, specimen tubes, and lab supplies

The test

What ENFD measures.

ENFD (also called intraepidermal nerve fiber density, or IENFD) testing uses a minimally invasive 3-mm skin punch biopsy — performed at CLIA-certified laboratories — to directly visualize and quantify small sensory nerve fibers in the epidermis.

The European Federation of Neurological Societies and the Peripheral Nerve Society guideline (2010) gives distal leg skin biopsy with intraepidermal nerve fiber density quantification its highest recommendation level (Level A) for diagnosing small fiber neuropathy.

“Distal leg skin biopsy with quantification of the linear density of intraepidermal nerve fibers (IENF), using generally agreed upon counting rules, is a reliable and efficient technique to assess the diagnosis of SFN (Recommendation Level A).”

Lauria G, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol 2010;17(7):903–912. PMID 20642627.

After the report

Confirming the diagnosis.

Confirming the diagnosis of SFN will allow the provider to evaluate possible underlying etiologies efficiently, and aggressively manage the symptoms.

Aggressive cause-specific treatment, lifestyle modifications, and pain control are key elements of managing SFN.

A normal skin biopsy result does not, by itself, rule out small fiber neuropathy. Biopsy findings should be interpreted in the context of the patient’s full clinical presentation.

Practice support

Training, billing, and reports.

  • 01

    Staff training

    The laboratory offers in-office staff training for the ENFD procedure.

  • 02

    Billing

    The laboratory offers direct billing to patient insurance plans. Coverage varies by insurance plan.

  • 03

    Reports

    Reports are typically returned within 10–15 business days.